[go: up one dir, main page]

MX2022013984A - Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). - Google Patents

Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Info

Publication number
MX2022013984A
MX2022013984A MX2022013984A MX2022013984A MX2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A
Authority
MX
Mexico
Prior art keywords
sup
nek7
inhibitors
compounds
kinase
Prior art date
Application number
MX2022013984A
Other languages
English (en)
Inventor
David James Bearss
Iii John Sai Keong Kauwe
Alexis Henri Abel Mollard
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of MX2022013984A publication Critical patent/MX2022013984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (ver Fórmula) (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable de los mismos, caracterizado porque A, X, Y, R1, R2, R3, R 4y R5 son como se definen aquí. También se proporcionan métodos asociados con la preparación y el uso de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para modular la actividad del inflamasoma NLRP3.
MX2022013984A 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). MX2022013984A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022159P 2020-05-08 2020-05-08
US202163170761P 2021-04-05 2021-04-05
PCT/US2021/031394 WO2021242505A1 (en) 2020-05-08 2021-05-07 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
MX2022013984A true MX2022013984A (es) 2023-01-30

Family

ID=77774963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013984A MX2022013984A (es) 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Country Status (25)

Country Link
US (3) US11161852B1 (es)
EP (1) EP4146348B1 (es)
JP (1) JP2023524597A (es)
KR (1) KR20230008763A (es)
CN (2) CN120699028A (es)
AU (1) AU2021280893A1 (es)
BR (1) BR112022022669A2 (es)
CA (1) CA3182276A1 (es)
CO (1) CO2022017622A2 (es)
DK (1) DK4146348T3 (es)
ES (1) ES2991366T3 (es)
FI (1) FI4146348T3 (es)
HR (1) HRP20241304T1 (es)
HU (1) HUE068185T2 (es)
IL (1) IL297979A (es)
LT (1) LT4146348T (es)
MX (1) MX2022013984A (es)
PH (1) PH12022553024A1 (es)
PL (1) PL4146348T3 (es)
PT (1) PT4146348T (es)
RS (1) RS65962B1 (es)
SI (1) SI4146348T1 (es)
TW (1) TW202208356A (es)
WO (1) WO2021242505A1 (es)
ZA (1) ZA202212146B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021280893A1 (en) * 2020-05-08 2023-01-05 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN114751874B (zh) * 2022-05-30 2025-01-24 江南大学 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
IL319000A (en) 2022-08-29 2025-04-01 Japan Tobacco Inc Pyrazolopyrimidine compounds and their medical use
US20240158394A1 (en) * 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2024249257A1 (en) * 2023-05-26 2024-12-05 Halia Therapeutics, Inc. Polymorphs of nek 7 inhibitors
TW202517271A (zh) * 2023-07-06 2025-05-01 美商哈利亞製藥公司 Nek7激酶抑制劑之醫藥組合物
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2025140570A1 (zh) * 2023-12-29 2025-07-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2025160453A1 (en) * 2024-01-25 2025-07-31 Halia Therapeutics, Inc. Heterocyclic compounds, such as ht-6184, for use in the treatment of pain
WO2025190317A1 (en) * 2024-03-13 2025-09-18 National Institute Of Biological Sciences, Beijing Urea compounds as nlrp3 agonists
CN118812538A (zh) * 2024-06-18 2024-10-22 南京健康产业研究院 一种具有抗肾癌活性的化合物及其制备方法与应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
MX2010001340A (es) 2007-07-31 2010-06-02 Schering Corp Combianacion de agente antimitotico e inhibidor de aurora quinasa como tratamiento anticancerigeno.
MX2010010172A (es) 2008-03-17 2010-11-25 Ambit Biosciences Corp Derivados de quinazolina como moduladores de quinasa raf y metodos de uso de los mismos.
TW201018682A (en) 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
CN102164916A (zh) 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 选择性调节cb2受体的磺酰基化合物
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2802212B1 (en) 2012-01-12 2015-12-30 Basf Se Herbicidal isoxazolo[5,4-b]pyridines
EP2997030B1 (en) 2013-05-14 2017-08-09 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CA2914815A1 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
US9290519B2 (en) 2013-11-15 2016-03-22 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
EA039885B1 (ru) 2014-11-14 2022-03-23 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
WO2016138473A1 (en) 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
JP6966423B2 (ja) 2015-04-24 2021-11-17 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
KR20180083323A (ko) 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
CN107176951A (zh) 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
US10167703B2 (en) 2016-03-31 2019-01-01 Saudi Arabian Oil Company Optimal well placement under constraints
DK3472165T3 (da) 2016-06-21 2023-12-11 Nerviano Medical Sciences Srl N-(substituererede-phenyl)-sulfonamidderivater som kinasehæmmere
BR112019001136A2 (pt) 2016-07-20 2019-04-30 Glaxosmithkline Ip Dev Ltd compostos químicos
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
JP2021506735A (ja) 2017-05-26 2021-02-22 イクノス サイエンシズ エスエー 新規ｍａｐ４ｋ１阻害剤
CA3066859A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3074381A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
US20210324067A9 (en) 2018-03-09 2021-10-21 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
BR112020018383A2 (pt) 2018-04-05 2020-12-29 Merck Patent Gmbh Compostos heteroarílicos como inibidores da irak tipo ii e usos dos mesmos
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
EP3837255B1 (en) 2018-08-14 2022-10-26 Samsung Display Co., Ltd. Organic molecules for optoelectronic devices
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CA3115088A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020113373A1 (en) 2018-12-03 2020-06-11 Zhuhai Qiwei Bio-Technology Ltd. Method of treating age-related macular degeneration
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
EP3908274A1 (en) 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3917907B1 (en) 2019-01-29 2025-05-21 Universitá Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
US11559536B2 (en) 2019-05-20 2023-01-24 Duke University Compositions and methods for the treatment of inflammation in urological pathology
KR20220066290A (ko) 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
KR102781651B1 (ko) * 2019-09-26 2025-03-18 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
US20230140941A1 (en) 2020-03-13 2023-05-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021184154A1 (en) * 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
US20230172941A1 (en) 2020-03-20 2023-06-08 The Johns Hopkins University Prophylaxis and treatment of pathogenic coronavirus infections
AU2021280893A1 (en) * 2020-05-08 2023-01-05 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
US20230210853A1 (en) 2020-05-08 2023-07-06 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
AU2021283577A1 (en) 2020-06-02 2023-01-19 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone β receptor agonist
TW202208368A (zh) 2020-06-08 2022-03-01 美商哈利亞製藥公司 Nek7激酶抑制劑
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP4232020A4 (en) 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
WO2022159835A1 (en) 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022192944A1 (en) 2021-03-15 2022-09-22 Genieus Genomics Pty Ltd Combination therapy for treatment of als
PH12023552774A1 (en) 2021-04-05 2024-04-15 Halia Therapeutics Inc Nek7 inhibitors
US20220380378A1 (en) 2021-04-22 2022-12-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2022232142A1 (en) 2021-04-26 2022-11-03 The Regents Of The University Of California G-alpha-s inhibitors and uses thereof
US20240287081A1 (en) 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
CN115616216B (zh) 2021-07-15 2025-08-12 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
JP2024525897A (ja) 2021-07-23 2024-07-12 ノバルティス アーゲー 変形性関節症の治療におけるｎｌｒｐ３阻害剤の投与計画
TW202333693A (zh) 2021-12-31 2023-09-01 大陸商上海翰森生物醫藥科技有限公司 苯并哌啶衍生物調節劑、其製備方法和應用

Also Published As

Publication number Publication date
KR20230008763A (ko) 2023-01-16
DK4146348T3 (da) 2024-09-30
PT4146348T (pt) 2024-10-04
AU2021280893A1 (en) 2023-01-05
TW202208356A (zh) 2022-03-01
CO2022017622A2 (es) 2022-12-20
ES2991366T3 (es) 2024-12-03
EP4146348A1 (en) 2023-03-15
CN115843272A (zh) 2023-03-24
FI4146348T3 (fi) 2024-09-25
CN120699028A (zh) 2025-09-26
JP2023524597A (ja) 2023-06-12
US20230416259A1 (en) 2023-12-28
HRP20241304T1 (hr) 2024-12-06
US20210355130A1 (en) 2021-11-18
US20220064173A1 (en) 2022-03-03
BR112022022669A2 (pt) 2023-01-17
US11713321B2 (en) 2023-08-01
IL297979A (en) 2023-01-01
EP4146348B1 (en) 2024-07-03
SI4146348T1 (sl) 2024-11-29
WO2021242505A1 (en) 2021-12-02
HUE068185T2 (hu) 2024-12-28
LT4146348T (lt) 2024-10-10
PH12022553024A1 (en) 2024-05-20
ZA202212146B (en) 2025-06-25
US11161852B1 (en) 2021-11-02
CN115843272B (zh) 2025-07-18
RS65962B1 (sr) 2024-10-31
CA3182276A1 (en) 2021-12-02
PL4146348T3 (pl) 2024-11-12
US12091413B2 (en) 2024-09-17

Similar Documents

Publication Publication Date Title
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
PH12023552774A1 (en) Nek7 inhibitors
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
MX2019013954A (es) Inhibidores covalentes de kras.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
MX2024000807A (es) Inhibidor de aak1 y uso de este.
MY209754A (en) Amide derivative and preparation method therefore and use thereof in medicine
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
CA3256658A1 (en) BICYCLE-DERIVED PARP INHIBITOR AND ITS USE
MX2024013914A (es) Moduladores del inflamasoma nlrp3 y productos y metodos relacionados
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals